Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical... Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical company engaged in the discovery and development of antibody-based drugs, with operations spanning South Korea and Sweden. The firm's developmental pipeline encompasses therapies derived from distinct technological platforms: the NEST platform addresses breast and gastric cancers; the AffiMab platform targets colon cancer and various autoimmune conditions; and the CAR-T platform is engineered for hematologic and ovarian cancers.
